Replies to post #417654 on Amarin Corp Plc (AMRN)

[Bouf]

What am I missing? Let’s say that the Brave study leads to another broad indication for V in treatment of Alzheimer’s. Why can’t generics steal that hypothetical market the same way they have stolen the CVD market even though they can only legally sell for the trig indication?

Bouf

[ziploc_1]

PDude...The National Institutes if Health is unlikely to embargo the results of the Brave study, done at the University of Wisconsin in conjunction with the Veterans Administration, until a presentation can be made at the NIH Alzheimers meeting in March 2024...I presume that, if the results of Brave are noteworthy, they will published by Dr. Carlsson soon after analysis of the study data is completed...This will afford time for the medical world to absorb the results of this very important study before discussion at the meeting.

A positive Brave study would make for a very interesting meeting indeed!